News
Public · Published
Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $26.4, Implies 59% Upside
Ultragenyx Pharmaceutical Inc.'s average 12-month stock price target rose from $26.25 to $26.4, based on estimates from 20 analysts. Relative to the Nov. 3 closing price, the updated target implies approximately 59% potential upside. The consensus rating remains Buy among 22 analysts.
Published:
Updated:
What happened
Ultragenyx Pharmaceutical Inc.’s average 12-month stock price target rose from $26.25 to $26.4, based on estimates from 20 analysts. Relative to the Nov. 3 closing price, the updated target implies approximately 59% potential upside. The consensus rating remains Buy among 22 analysts.
Confirmed
Global impact / market context
The higher target signals that surveyed analysts have modestly increased their expected value for Ultragenyx shares, while the Buy consensus is unchanged. If investors act on those expectations, share demand could rise, but the target is a forecast rather than a guaranteed return.
Analyst inference
The estimates vary widely, from $16 to $39 per share, showing that analysts do not agree on a single valuation. Ratings are also split evenly between 11 Buys and 11 Holds, with no Sells, so the headline target increase does not represent a stronger rating consensus.
Confirmed
What to watch
- Future analyst targets and ratings could show whether the average estimate continues to rise or reverses, and whether the current balance of Buys and Holds changes. Analyst inference
- Compare any later target with the share price used at that time; the reported 59% potential upside is based specifically on the Nov. 3 closing price. Confirmed
- Watch for company updates that could affect analysts’ expectations for revenue, costs, or cash available, since revised business outlooks may lead them to change their targets. Analyst inference
Evidence
- Original source link unavailable